Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence

Abstract

Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.

Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta‐analysis

“…Since the advent of Sacubitril/Valsartan, its benefits for the HFrEF patients and the HF with preserved ejection fraction patients have been confirmed in PARADIGM-HF study and PARALLAX study, respectively. 18,19 The activation of RAAS is the main determinant of the pathophysiology of AMI and HF. Considering that Sacubitril/ Valsartan could inhibit the activation of RAAS, many researchers hypothesized that Sacubitril/Valsartan have benefits in patients after AMI.…”

Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17 and Neprilysin as Effectors in Keloid Formation

“…The strong appearance of activated proteases in keloid lesions implies that these molecules may constitute an ideal target for future therapies. Protease inhibitors have been developed, are in clinical trials and have reached the market [41,42]. It is certainly worthwhile to test such drugs for local injection or systemic therapy during the wound healing process of keloid-affected patients.…”

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis

“…The decision on further dose management should be followed by an evaluation of renal function and potassium levels. 8 , 9 , 10 …”